Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 PK Study with Itraconazole
NCT07186452Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of risvutatug rezetecan in solid tumor (advanced stage), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum plasma concentration at 9 weeks and Area under the concentration-time curve from 0 to 16 days. Started Sep 2025; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07186452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07186452.